STAT+: The near-term outlook for pharma industry earnings just got a little worse
The near-term earnings outlook for the pharmaceutical industry was revised downward by a major credit…
Category: biotechnology
STAT+: New analysis of Amarin’s Vascepa resurrects big questions about effectiveness
A new analysis of Vascepa, a medicine derived from fish oil and used to prevent…
.jpg)
Lattes and gummies: Food science inspires a new approach to treating gut and liver injury
Inspired by how coffee shops foam milk, as well as gummy candy and sizzling Pop…
STAT+: ARCH Venture Partners raises $3 billion fund to invest in biotech startups despite brutal stock downturn
The market for biotechnology stocks is ghastly, but ARCH Venture Partners, one of the largest…
STAT+: Pharmalittle: Sarepta halts a Duchenne clinical trial over safety; Why the CVS Health whistleblower lawsuit comes at a pivotal moment
And so, another working week will soon draw to a close. Not a moment too…
STAT+: FDA halts study of Sarepta treatment for Duchenne muscular dystrophy due to safety concern
Sarepta Therapeutics said Thursday that it has temporarily stopped a clinical trial of its second-generation…
Listen: Juul’s doomsday, Merck’s buyout plans, & the next Theranos verdict
Just how powerful is the FDA? Is Merck about to spend $40 billion? And what’s…
STAT+: A cautionary tale: How one biotech stock trader lost a small fortune, but emerged wiser
Too many of my Twitter interactions with biotech-loving retail investors are unpleasant. If I write…
STAT+: Uniqure’s Huntington’s gene therapy lowers key protein in small trial
A gene therapy for Huntington’s disease made by the Dutch biotech firm Uniqure showed early…
STAT+: With cryptocurrency and NFTs, ‘decentralized science’ seeks to upend drug industry financing
When Alok Tayi’s daughter was born last year, he found himself in a place no…
STAT+: Startup will target cystic fibrosis with a new twist on gene therapy
Gene therapy developers rely on hollowed-out viruses to shuttle DNA into the body, where it…
STAT+: PTC’s Duchenne muscular dystrophy drug achieves study goal, potentially confirming European approval
PTC Therapeutics said Tuesday that its treatment for Duchenne muscular dystrophy slowed the loss of…
STAT+: Pharmalittle: Merck is eyeing Seagen to beef up its cancer drug portfolio; Lawmakers want GAO to probe PBMs
Good morning, everyone, and welcome to another working week, although today is actually a holiday…
STAT+: A longtime investor talks interest rates, biotech, and why luxury cars are a warning sign
This week the central bank hiked interest rates by three quarters of a percentage point,…
Listen: Paul Offit on Covid vaccines for kids, plus: how the Fed affects biotech, & another Alzheimer’s setback
Will biotech stocks ever recover? How well do Covid-19 vaccines work for kids? And can…
STAT+: A Roche treatment fails to slow cognitive decline in patients with inherited form of Alzheimer’s disease
Roche reported negative results Thursday from a long-running clinical trial investigating an experimental antibody treatment…
STAT+: Third Rock Ventures plots next chapter after raising $1.1 billion fund
Third Rock Ventures has raised $1.1 billion for its largest-ever fund, the biotech venture capital…
STAT+: Amylyx’s case for approval of its ALS drug isn’t ironclad. Here’s why I think it will still happen
The odds that Amylyx Pharmaceuticals wins approval from the Food and Drug Administration for Albrioza,…
Eli Lilly wins FDA approval for first-ever treatment for hair loss caused by autoimmunity
The Food and Drug Administration on Monday approved an Eli Lilly drug that is the…
STAT+: In early trial, drug shrinks tumors in majority of children with most common form of brain cancer
Day One Biopharmaceuticals reported Sunday that an experimental molecule shrank tumors by at least 50%…
STAT+: Canada approves ALS drug from Amylyx Pharma as U.S. patients await extended review
Amylyx Pharmaceuticals secured approval in Canada on Monday for a new medicine to treat patients…
STAT+: Biotech is practically in San Diego’s DNA. Here’s how it got there — and how it might evolve
SAN DIEGO — More than 40 years ago, Ivor Royston, a brash young assistant professor…
STAT+: Updated study results show a CRISPR treatment for blood diseases continues to benefit patients
Updated results announced Saturday from two clinical trials involving an experimental, genome-editing treatment showed prolonged…
STAT+: FDA advisers endorse Bluebird gene therapy for rare blood disorder
A panel of advisers to the Food and Drug Administration voted unanimously to recommend approval…
FDA advisers unanimously endorse Bluebird’s gene therapy for rare disorder
Advisers to the Food and Drug Administration voted unanimously in favor of approving an investigational…
.jpg)
STAT+: BioSpring Partners closes $245 million first fund as private markets tense up
When Michelle Dipp and Jennifer Lum decided to launch a life sciences growth equity fund…
STAT+: Watch: An interview with the FDA’s top cancer regulator
On Friday, Richard Pazdur, the director of the FDA Oncology Center of Excellence, sat down…
STAT+: Praxis’ novel antidepressant fails make-or-break trial
A novel antidepressant from Praxis Precision Medicines failed to outperform placebo in a pivotal study,…
STAT+: Adicet ‘gamma-delta’ T cell therapy shows complete remissions in early study of lymphoma patients
CHICAGO — Adicet Bio reported Monday that a unique, off-the-shelf therapy made from a special…
With the right molecular signal, a cancer drug works in every patient
Sascha Roth was in her late 30s and feeling great. Then she noticed some bleeding…
STAT+: Roche’s Tigit troubles escalate, sparking more debate about the closely tracked cancer immunotherapy target
CHICAGO — Roche had previously announced the failure of its closely tracked anti-TIGIT immunotherapy in…
STAT+: Promising results reported for new generation of CAR-T immunotherapy for myeloma
CHICAGO — Three companies presented Phase 1 clinical trial results on new CAR-T therapies for…
STAT+: Enhertu, a smart bomb drug, dramatically extends survival in breast cancer patients
CHICAGO — The cancer drug Enhertu cut the rate of death in a group of…
STAT+: In study, Gilead’s Trodelvy shows modest benefit in breast cancer patients
CHICAGO — The cancer drug Trodelvy reduced the risk of tumors progressing by 34% compared…
STAT+: The FDA’s Pazdur on accelerated approval, single-arm studies, and his own future
CHICAGO — When cancer drugs granted accelerated approval in the U.S. later turn out not…
STAT+: Strategist Jared Holt on why innovation may not be such a good thing for the biotech sector
Every year, the meeting of the American Society of Clinical Oncology, or ASCO, is one…
STAT+: Neumora, ambitious startup focused on neuroscience, considers filing for an IPO
Neumora Therapeutics, the neuroscience company launched last year in a bid to revitalize a field…
Listen: Biotech’s catch-22, a $100 genome, & dealing with monkeypox
Will gene therapy ever live up to expectations? Can anyone break up the genomics monopoly?…
STAT+: Companies can’t make CAR-T cells for cancer treatment quickly enough. Here’s what they’re doing about it
The shortage of manufacturing slots for CAR-T cells, which has left myeloma patients dying on…
‘How do you decide?’: Cancer treatment’s CAR-T crisis has patients dying on a wait list
Within two years of being diagnosed with multiple myeloma, Shawn Goltzene had blasted through nearly…
STAT+: More and more biotechs are worth less than their checking accounts
Biotech’s 2021 swoon has settled into a 2022 malaise, with the closely watched XBI index…
STAT+: Theranos whistleblower Tyler Shultz on lessons learned, venture capital, and shutting down his own business
SAN FRANCISCO — During the worst moments at Theranos, Tyler Shultz ran. To burn off…
STAT+: A ‘dark horse’ emerges in the DNA sequencing race, boasting a $100 genome
Bay Area biotech Ultima Genomics on Tuesday claimed that its technology can sequence a whole…
STAT+: With new data on its KRAS-blocking lung cancer drug, Mirati expects to take on a rival Amgen treatment
As Mirati Therapeutics waits for the Food and Drug Administration to complete a review of…
Listen: Covid vaccines for the youngest kids, ASCO preview, & a biotech CEO’s arrest on murder charges
Covid vaccines for the youngest kids are up for review, but which jab — Moderna…
STAT+: Flagship’s latest startup launches with bold claim: the discovery of thousands of new human proteins
A Cambridge, Mass., biotech company claims to have made a discovery that could rewrite biology…
STAT+: ‘No real clear path’: Insurance coverage for cutting-edge diagnostics remains a major challenge for personalized medicine
DANA POINT, Calif. — Even the best treatment for a disease is no help if…
Listen: Mysterious infections, dwindling Covid funds, & Shkreli out of prison
What happens when the White House runs out of Covid-19 money? Why are kids suddenly…
STAT+: Apollo acquires minority stake in Sofinnova, extending private equity dealmaking in life sciences
Private equity giant Apollo Global Management is spending $1 billion for a piece of one…
STAT+: Seagen CEO resigns after arrest on domestic assault charges
Clay Siegall, co-founder and CEO of Seagen, has resigned in the wake of his arrest…